Publicaciones en las que colabora con Jesús García-Foncillas López (28)

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2016

  1. PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma

    Pathology and Oncology Research, Vol. 22, Núm. 2, pp. 377-383

2014

  1. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool

    Neuro-Oncology, Vol. 16, Núm. 4, pp. 520-527

2013

  1. KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients

    Oncology Letters, Vol. 6, Núm. 5, pp. 1343-1345

  2. Valoración de marcadores pronósticos de respuesta a bevacizumab en pacientes con cáncer colorrectal avanzado y su utilidad para la individualización del tratamiento

    Anales del sistema sanitario de Navarra, Vol. 36, Núm. 1, pp. 174-177

2012

  1. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

    European Journal of Cancer, Vol. 48, Núm. 12, pp. 1774-1780

  2. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593

  3. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array

    World Journal of Gastroenterology, Vol. 18, Núm. 7, pp. 637-645

  4. Identification of predictive circulating biomarkers of bevacizumab- containing regimen efficacy in pre-treated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 107, Núm. 2, pp. 287-290

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  2. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells

    Stem Cells, Vol. 29, Núm. 11, pp. 1661-1671

  3. Patterns of response after preoperative treatment in gastric cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 80, Núm. 3, pp. 698-704

2010

  1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  2. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab

    Critical Reviews in Oncology/Hematology, Vol. 74, Núm. 3, pp. 193-202

  3. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation

    Molecular Cancer Therapeutics, Vol. 9, Núm. 8, pp. 2265-2275

2009

  1. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells

    Clinical Cancer Research, Vol. 15, Núm. 7, pp. 2281-2290

2008

  1. Phase I-II Trial of Concurrent Capecitabine and Oxaliplatin With Preoperative Intensity-Modulated Radiotherapy in Patients With Locally Advanced Rectal Cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 71, Núm. 3, pp. 748-755

2007

  1. Combining chemotherapy and targeted therapies in metastatic colorectal cancer

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5867-5876

  2. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new?

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5877-5887